NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis $3.25 -0.13 (-3.85%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.19▼$3.4550-Day Range$3.23▼$5.5552-Week Range$3.14▼$21.88Volume533,910 shsAverage Volume1.70 million shsMarket Capitalization$203.56 millionP/E RatioN/ADividend YieldN/APrice Target$8.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get MacroGenics alerts: Email Address MacroGenics MarketRank™ Stock AnalysisAnalyst RatingHold2.30 Rating ScoreUpside/Downside149.6% Upside$8.11 Price TargetShort InterestBearish10.69% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews Sentiment0.02Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.72) to ($2.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.16 out of 5 starsMedical Sector141st out of 910 stocksPharmaceutical Preparations Industry51st out of 426 stocks 4.2 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageMacroGenics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MacroGenics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.69% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in MacroGenics has recently decreased by 0.64%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 2.2 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for MacroGenics this week, compared to 7 articles on an average week.Search InterestOnly 2 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat Follows3 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MacroGenics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($1.72) to ($2.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -8.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -8.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MacroGenics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About MacroGenics Stock (NASDAQ:MGNX)MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Read More MGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGNX Stock News HeadlinesSeptember 7 at 11:15 AM | prnewswire.comMacroGenics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Deadline in Securities Fraud Class Action LawsuitSeptember 6 at 12:19 PM | globenewswire.comMacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial – Hagens BermanSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 6 at 5:45 AM | prnewswire.comContact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX)September 6 at 2:01 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 5 at 12:47 PM | globenewswire.comClass Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & KorsinskySeptember 5 at 5:45 AM | prnewswire.comInvestors who lost money on MacroGenics, Inc.(MGNX) should contact The Gross Law Firm about pending Class Action - MGNXSeptember 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNXSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 3, 2024 | globenewswire.comMGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 3, 2024 | prnewswire.comMGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 3, 2024 | prnewswire.comInvestors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNXSeptember 2, 2024 | prnewswire.comMGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud LawsuitSeptember 2, 2024 | globenewswire.comMacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens BermanSeptember 2, 2024 | globenewswire.comMacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPSeptember 1, 2024 | prnewswire.comKessler Topaz Meltzer & Check, LLP Notifies MacroGenics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action LawsuitAugust 31, 2024 | globenewswire.comROSEN, A TOP-RANKED LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNXAugust 31, 2024 | prnewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenicsSee More Headlines Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees430Year Founded2000Price Target and Rating Average Stock Price Target$8.11 High Stock Price Target$14.00 Low Stock Price Target$4.00 Potential Upside/Downside+149.6%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,060,000.00 Net Margins-332.47% Pretax Margin-332.47% Return on Equity-146.01% Return on Assets-68.53% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.69 Sales & Book Value Annual Sales$39.46 million Price / Sales5.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book3.53Miscellaneous Outstanding Shares62,633,000Free Float55,555,000Market Cap$203.56 million OptionableOptionable Beta2.09 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Scott Koenig M.D. (Age 72)Ph.D., President, CEO & Director Comp: $1.2MMr. James Karrels (Age 57)Senior VP, CFO & Corporate Secretary Comp: $693.31kDr. Stephen L. Eck M.D. (Age 69)Ph.D., Senior VP of Clinical Development & Chief Medical Officer Comp: $766.85kMr. Eric Blasius Risser (Age 51)Chief Operating Officer Comp: $651.36kDr. Thomas M. Spitznagel Ph.D. (Age 57)Senior Vice President of Technical Operations Comp: $550.97kDr. Ezio Bonvini M.D. (Age 70)Senior VP of Research & Chief Scientific Officer Comp: $612.21kMr. Jeffrey Stuart Peters (Age 53)Senior VP, General Counsel & Corporate Compliance Officer Ms. Lynn Cilinski (Age 66)VP, Controller & Treasurer More ExecutivesKey CompetitorsEpizymeNASDAQ:EPZMRepare TherapeuticsNASDAQ:RPTXPuma BiotechnologyNASDAQ:PBYIIntercept PharmaceuticalsNASDAQ:ICPTZymeworksNYSE:ZYMEView All CompetitorsInsiders & InstitutionsFrazier Life Sciences Management L.P.Bought 539,023 shares on 8/16/2024Ownership: 4.807%Armistice Capital LLCBought 3,600,000 shares on 8/15/2024Ownership: 9.580%Millennium Management LLCBought 3,219,977 shares on 8/15/2024Ownership: 5.289%AQR Capital Management LLCBought 61,131 shares on 8/15/2024Ownership: 0.229%Susquehanna Fundamental Investments LLCBought 24,209 shares on 8/15/2024Ownership: 0.208%View All Insider TransactionsView All Institutional Transactions MGNX Stock Analysis - Frequently Asked Questions How have MGNX shares performed this year? MacroGenics' stock was trading at $9.62 at the beginning of 2024. Since then, MGNX stock has decreased by 66.2% and is now trading at $3.25. View the best growth stocks for 2024 here. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.42. The biopharmaceutical company earned $10.80 million during the quarter, compared to analyst estimates of $24.14 million. MacroGenics had a negative trailing twelve-month return on equity of 146.01% and a negative net margin of 332.47%. What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. Who are MacroGenics' major shareholders? MacroGenics' top institutional investors include Armistice Capital LLC (9.58%), Millennium Management LLC (5.29%), Frazier Life Sciences Management L.P. (4.81%) and Dimensional Fund Advisors LP (1.43%). Insiders that own company stock include Target N V Biotech, James Karrels, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE). This page (NASDAQ:MGNX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
